Novo Nordisk Advances Subcutaneous And Oral Amycretin to Phase 3 for Obesity Management

Novo Nordisk has announced its plans to advance both subcutaneous and oral formulations of amycretin into phase 3 clinical development for weight management. The decision follows the completion of phase 2 studies and positive feedback from global regulatory authorities, including during recent end-of-phase 2 meetings.

“We are very pleased that the feedback from regulatory authorities has allowed us to take subcutaneous and oral amycretin in weight management to phase 3,” said Martin Lange, executive vice president for Development at Novo Nordisk. “We are excited about the amycretin molecule, and this marks an important step forward. We look forward to sharing more information on the design of the phase 3 programme.”

Amycretin, part of Novo Nordisk’s next-generation obesity pipeline, has demonstrated promising results in previous trials, potentially offering an innovative treatment option for adults with overweight or obesity.  Novo Nordisk has now announced that it plans to start a phase 3 development programme with amycretin in adults with overweight or obesity in the first quarter of 2026.